Anti-Neoplastics #5 Flashcards

1
Q

Describe apoptosis in a normal, healthy cell.

A

▪ It is a highly regulated process
▪ Depend on the balance of pro-apoptotic and pro-survival signals
▪ Internal surveillance molecules detect damaged DNA and
signal cells for suicide
▪ Biochemical events of apoptotic cell: cell shrinkage, chromatin
condensation, DNA fragmentation etc
▪ Cells convert to vesicle that can be removed by macrophages

One of the major characteristics of chemotherapy drugs is can they induce apoptosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe apoptosis in a cancerous cell.

A

▪ Cancer cells alter pro-apoptotic proteins that detect problems and induce apoptosis (Caspases, Bad, Bax, Bak, Noxa, Puma)
▪ Overproducing anti-apoptotic proteins (belonging to the following classes: BCL-2, MCL-1, BAG-3, HSP 27 and 70, survivin etc)
▪ Creating mutant proteins. Even if there is pro-apoptotic protein, it can be mutated in cancer cells; does not do its job aka cause apoptosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

In the process of apoptosis, the extrinsic pathway and intrinsic pathway come together and form the execution phase.

A

Activation of apoptotic pathways are avoided in cancer. We want to activate this pathway which is the key mechanisms by which cytotoxic drugs kill cancer cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the major goal of apoptotic pathway? What are these drugs classified as?

A

The Goal: Switch the balance towards cell death for cancer cells
▪ Drugs that directly activate pro-apoptotic pathways (Bax, Bak, Bad, and Bok) to cause apoptosis
▪ Drugs that deactivate anti-apoptotic proteins (BCL-2, Bcl-xl) present in cancer cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is Palladia?
What is its generic name?
What is its MOA?
What is it used for?
**What are the adverse effects?

A

Targeted drugs are more often used as a primary treatment for some cancers but more often used in combination with surgery, radiation, standard chemo.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is Laversia-CA1R (Verdinexor)?

A

Laversia-CA1R (Verdinexor): is the first small-molecule selective inhibitor of nuclear export (SINE), which targets and binds to Exportin-1 (XPO1) transporter. This transporter is important for cell functioning.

It is the first and ONLY oral tablet to treat lymphoma in dogs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What drug is used off-label as a form of targeted therapy in cats?

A

GleevacR (Imatinib) is used in cats (off label): binds and inhibits several protein-tyrosine kinases in squamous cell carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is Angiogenesis?
What is the role of this process in adults?
What nutrients does this process need?
What do these new cells release?

A

▪ Angiogenesis is increased BV formation. It is a highly regulated process, takes place in early development.
▪ In adults: promote wound healing and support female reproduction system in pregnancy
▪ On cellular level angiogenesis happen when cell is in need of nutrients & O2
**▪ Cell releases proteins that bind to special receptors in the surface of endothelial cells (EC) that make up the lining of the vessels. Endothelial cells line the vessels and these cells express pro-angiogenic factors. Therefore, drugs will take action on these EC. This is the difference between other targeted drugs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the role of angiogenesis in cancer cells?

A

▪ Tumor blood vessels provide nutrition and oxygen
▪ Cancer cells “attract” angiogenesis by producing high levels of proteins such as VEGF, MMPs, HIF-1α
▪ Endothelial cells (EC) express receptors that respond to this proteins

Drugs, MABS, act to neutralize the growth promoting effect of the tumor micro-environment which can affect the immune system and other systems in the body.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the goal of Anti-Angiogenic Therapy?
What are the two classes of drugs used in this form of therapy?
What other classes of drugs can be used?
What is the ideal anti-angiogenic drug?

A

The Goal: Block angiogenesis to starve tumor. May be an ideal strategy for cancer therapy b/c it can have less effects on other normal cells than chemotherapy.
▪ Drugs that interfere with any tumor cells (indirect inhibitors –> block activity of angiogenesis inducers = cytokines, oncogenes, growth factors, cells in tumor microenv, etc.) and tumor endothelial cells (EC) (direct inhibitors –> tatget EC cells). Anti-angiogeneic are usually used as combination therapy b/c we still do not have ideal drug.
▪ Drugs that target pro-angiogenic proteins released by tumor (ligand)
▪ Drugs that target endothelial receptors (EC)
▪ Ideal anti-angiogenic drug can target all cancers (EC are the same in all cancers)
▪ Less drug resistance since EC are genetically stable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is AvastinR (Bevacizumab)?

A

target VEGF, so it is an anti-VEGF antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is NexavarR (Sorafenib)?

A

target VEGF-R and has kinase activity (small molecule inhibitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe how you can use anti-angiogenic therapy to prevent angiogenesis?

A

VEG-F binds to VEGF-R and promotes signaling pathway –> angiogenesis. If you block the ligand, VEG-F, or block the receptor with Sorafenib and Sorafenib, angiogenesis is inhibited.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Anti-Angiogenic mAbs may be therapeutically efficacious
in?

A

inhibiting the growth of canine sarcomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the mechanism of action of Bevacizumab (AvastinR)?

A

Inhibit binding of VEGF to its receptor
on EC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the mechanism of action of Sorafenib (NexavarR); Sunitinib
(SutentR)?

A

Inhibit multiple kinases in EC

17
Q

What is the MOA of MMPs?

A

Inhibit basement membrane
degradation

18
Q

What is the MOA of Thrombospondin?

A

Inhibit cell migration, proliferation,
adhesion and survival of EC

19
Q

What is the MOA of Angiostatin?

A

Inhibit cell proliferation and induce
apoptosis of EC

20
Q

What is the MOA of Endostatin?

A

Inhibit cell migration, cell proliferation
and survival of EC

21
Q

What is immunotherapy? What are the side effects?

A

Immunotherapy trains the immune system to attack cancer,
rather than attacking the cancer directly.
Side effects often differ from those commonly seen with other types of cancer treatment:
❖ Fatigue
❖ Inflammation (skin; lungs (cough and chest pains); colon (abdominal pain and diarrhea)
❖ Endocrine system: diabetes; inflammation of the pituitary gland

22
Q

How does a cancerous tumor trick T cells?

A
23
Q

How does immunotherapy work?

A
24
Q

Cancers learn to hijack the breaks of T cells. T cells have different receptors which tell them to go fight or to stop and don’t fight. We can increase the signal to fight or we can inhibit the signal to not fight.

These receptors, which are either stimulatory or inhibitory, are called immune check point proteins. Cancer cells have a ligand for PD-1 called PDL-1. This way, cancer deactivates the T cells. If we use a drug called checkpoint inhibitors that can block this blocking action, T cells can fight.

A
25
Q

What are the functions of the following drugs:
Ipilimumab, Nivolumab, Pembrolizumab?

A
26
Q

Why is targeting PDL-1 important in immunotherpay?

A

PD-L1 is expressed in many canine tumors including:
**Malignant melanoma
Mammary gland tumors
Osteosarcoma
Hemangiosarcoma
Mast cell tumors
Histiocytic sarcoma
Renal cell carcinoma
Lymphoma
Soft tissue sarcoma
▪ PD-1/PD-L1 blockade by mAb therapy may be an attractive option in canine cancer therapy
▪ Development and characterization of mAb against canine PD-1 and PD-L1
▪ mAb therapy represents one of the most promising avenues for the
development of veterinary immunotherapy.

27
Q

What is Oncolytic Viral Therapy?

A

Selectively infect and kill cancer cells, with very little effect on healthy cells.
Oncolytic viruses have immune-stimulatory properties. This combo can be used in dogs.
E.g. zika virus is introduced into CSF against brain tumors in dogs. Other viruses are being used against mammary gland tumors and osteosarcomas in dogs.

28
Q

What is Adaptive Cell Therapy (ACT)?

A

Main idea: activation and expansion of antitumor immunce cells in vivo by doing exvivo things.
You resect tumor samples and prepare single cell suspension which has more immune abilities to fight tumor. You grow them in lab and put back into the dog, and humans too. This can be done in diff ways, either T cells harvested from blood of patient and manipulating them to become more active and putting back into patient so immune cells can fight tumor.

Used in leukemias, lymphomas; bone marrow toxicity, GI side effects. Very expensive.

29
Q

What is the purpose of using anti-cancer vaccines?

A

▪ Activate bodies immune system to recognize and kill cancer cells
▪ Cancer vaccines work systemically to activate immune system, not on particular
target
▪ Therapeutic vaccine: APCs (dendritic cells), activation of T-cells
▪ First FDA-approved [Sipuleucel-T (Provenge); prostate cancer, humans]
▪ There is a therapeutic DNA-based vaccine for canine melanoma (in trials)

30
Q

Anti-cancer vaccine strategies

A

Vaccination strategies. Vaccines utilize a variety of strategies to activate the immune system
against tumor associated antigens (TAAs).The TAAs must then be presented by to T cells. Once
activated, T cells must traffic to the tumor and induce tumor cell death

31
Q

Anti-Cancer Vaccines challenges

A

Challenges: T cell tolerance to TAAs, dysfunctional antigen presentation, T-cell exhaustion induced by checkpoint inhibitors (such as PD-1), and immunosuppressive cells in the tumor microenvironment may all result in suppression of the immune response and variable patient responses to vaccination

32
Q

What is the first therapeutic cancer vaccine?

A

Canine oral malignant melanoma (OMM): the first therapeutic cancer vaccine, 2007 (Conflicted data from different trials)

Although cancer vaccine trials have had more failures than successes, the responses seen in a subset of patients demonstrate the potential to induce an anti-tumor immune response under the right circumstances